Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Fetal Fibronectin: Its Role in Threatened Preterm Labor
    ABSTRACT & COMMENTARY

    Fetal Fibronectin: Its Role in Threatened Preterm Labor

    March 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Does Cervicovaginal Fetal Fibronectin Really Play a Role in the Diagnosis of Preterm Labor?

    Use of Cervical Length and Fetal Fibronectin in Preterm Labor

    A Comparison of Speculum and Non-speculum Collection Methods of Cervicovaginal Specimens for Fetal Fibronectin Testing

    Related Products

    Abortion for Fetal Anomalies: Trends in Gestational Age

    Induction of Labor in Patients with Previous Cesarean Sections

    Keywords

    preterm

    fibronectin

    By John C. Hobbins, MD

    Professor, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora

    Dr. Hobbins reports no financial relationships relevant to this field of study.

    SYNOPSIS: A recent letter to the editor disputes the conclusion of an earlier study that fetal fibronectin is of little value in threatened preterm labor, despite other studies suggesting that when used in conjunction with cervical length measurements, it can diminish unnecessary hospitalizations appreciably.

    SOURCE: van Baaren GJ, Bruijn MMC, Mol BW, et al. Randomized trials are not always the best way to assess diagnostic tests: The case of fetal fibronectin testing. Am J Obstet Gynecol 2017; Nov. 21. pii: S0002-9378(17)31230-9. doi: 10.1016/j.ajog.2017.10.037. [Epub ahead of print].

    The featured letter to the editor, along with two responses,1,2 were published in the January issue of the American Journal of Obstetrics and Gynecology, all pertaining to a 2016 article by Berghella et al3 about the use of fetal fibronectin (fFN) in patients with threatened preterm labor (PTL). This interplay provided very interesting commentary regarding the interpretation of the original study results and the benefits/shortcomings of randomized, controlled trials (RCTs) and observational studies. First, the index study: Berghella et al trolled the Cochrane database for RCTs involving fFN alone as a predictor of preterm delivery < 37 weeks.3 They found six studies that satisfied their inclusion requirements. These studies all involved patients being evaluated for threatened PTL. Half of 546 patients, who were between 23 and 35 weeks’ gestation, were randomized to having fFN testing available to their managing providers shortly after the patients presented. In the other half, the test results were not available. None of the studies dealt with cervical length (CL) measurements. In three studies, a common protocol for management and/or therapy was used, but in the remaining three studies, the management was ad lib.

    The authors found no statistically significant differences in the rates of delivery < 37 weeks (their primary outcome measure), delivery < 32 weeks, length of hospitalization, use of steroids or tocolytics, neonatal respiratory distress syndrome, or length of neonatal stays. The only difference was an average increased cost of $153 per patient in the fFN group. The authors’ concluded that use of fFN was not associated with a decrease in preterm birth or any improvement in perinatal outcome.

    In a companion editorial in the same issue, Macones went one step further in suggesting that the use of fFN in threatened preterm labor cannot be justified.4

    COMMENTARY

    The above study and editorial sparked the featured letter to the editor in this month’s issue of the American Journal of Obstetrics and Gynecology from van Baaren and colleagues, who pointed out that most patients with threatened PTL are not in labor and the benefit of selectively used fFN is in its high negative predictive value (NPV). Their own observational study showed that a negative fFN, used in conjunction with CL in this setting, would allow most patients to be discharged safely without the need for tocolysis or steroids.5 They believed that before concluding that fFN was worthless in threatened PTL, the study should include a uniform management protocol regarding how to deal with the results of the fFN test.

    In response to this letter to the editor, both Berghella and Macones seemed to agree with van Baaren that a predictive test such as fFN alone cannot change an outcome unless it segues into some type of action that works. Steroids do not stop PTL and even the overall benefit of tocolysis in PTL has been questioned over the years. However, Macones noted that the investigative power of RCTs was superior to observational studies, since they show what “does” happen with a particular test or action, rather than what “could” happen (with observational studies).

    After wading through the entertaining collegial jousting, it should be clear that fFN does not have significant benefit in a vacuum. However, when used selectively in conjunction with CL in a regimented protocol — as suggested by van Baaren in the letter to the editor, Berghella in his response to the letter to the editor,1 and in a 2007 RCT for which Berghella was an author6 — it “will” decrease unnecessary hospitalizations, interventions, and healthcare costs.

    If using fFN, the following is a re-formatted evaluation of threatened PTL initially suggested by van Baaren et al:5 On initial evaluation, patients with painful preterm contractions can have a sample taken with a swab from the posterior fornix of the vagina, which will be held in abeyance until the rest of the initial evaluation has been completed. This would include transvaginal sonography, in conjunction with a pelvic exam, to assess the status of the cervix. A CL < 1.5 cm would suggest the need for hospital admission (and the swab would be discarded since fFN would offer no additional benefit). If CL > 3 cm, the high NPV of this measurement alone would not be enhanced by fFN and the patient could be discharged. However, if the cervical length is between 1.5 cm and 3.0 cm, a positive fFN result would trigger admission and a negative result would mean that the patient would simply be followed carefully with outpatient visits.

    Although both RCTs and observational studies have strong merit alone, they are, in fact, linked symbiotically. Often, an evidence-based evaluation of a concept or method can be accomplished only through an RCT. However, without observational studies there would be no concepts to test. Also, at times, the data from an observational study are so compelling — and the likelihood is so low of getting the results tested through a timely, flawlessly designed RCT — that management could be guided legitimately by the results of the observational study. The focus should not necessarily be on whether fFN decreases the rate of preterm birth, but should be on whether it can keep patients from having an unnecessary (and disruptive) hospitalization at a time when healthcare costs are out of control.

    REFERENCES

    1. Berghella V, Saccone G. Reply L17-093AR1. Am J Obstet Gynecol 2017; Nov. 4. pii: S0002-9378(17)31231-0. doi: 10.1016/j.ajog.2017.10.038. [Epub ahead of print].
    2. Macones GA. Reply. Am J Obstet Gynecol 2017; Nov 4. pii: S0002-9378(17)31232-2. doi: 10.1016/j.ajog.2017.10.039. [Epub ahead of print].
    3. Berghella V, Saccone G. Fetal fibronectin testing for prevention of preterm birth in singleton pregnancies with threatened preterm labor: A systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol 2016;215:431-438.
    4. Macones GA. Fetal fibronectin testing in threatened preterm labor: Time to stop. Am J Obstet Gynecol 2016;215:405.
    5. van Baaren GJ, Vis JY, Wilms FF, et al. Predictive value of cervical length measurement and fibronectin testing in threatened preterm labor. Obstet Gynecol 2014;123:1185-1192.
    6. Ness A, Visitine J, Ricci E, Berghella V. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial. Am J Obstet Gynecol 2007;197:426.e1-7.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    OB/GYN Clinical Alert

    View PDF
    OB/GYN Clinical Alert (Vol. 34, No. 11) – March 2018
    March 1, 2018

    Table Of Contents

    Fetal Fibronectin: Its Role in Threatened Preterm Labor

    Which Antibiotics Are Safe in the First Trimester of Pregnancy?

    Oxytocin Discontinuation

    Prevalence of Cognitive Impairment in Older Women With Pelvic Floor Disorders

    Begin Test

    Buy this Issue/Course

    Clinical Briefs in Primary Care

    Pharmacology Watch

    Financial Disclosure: OB/GYN Clinical Alert’s Editor, Jeffrey T. Jensen, MD, MPH, reports that he is a consultant for and receives grant/ research support from Bayer, Merck, ContraMed, and FHI360; he receives grant/research support from Abbvie, HRA Pharma, Medicines 360, and Conrad; and he is a consultant for the Population Council. Peer Reviewer Catherine Leclair, MD; Nurse Planners Marci Messerle Forbes, RN, FNP, and Andrea O’Donnell, FNP; Editorial Group Manager Terrey L. Hatcher; Executive Editor Leslie Coplin; and Editor Journey Roberts report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing